{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-243046","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2025-10-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.864481+00:00","generated_at":"2026-05-17T03:13:37.300837+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Corbus Pharma reports CRB-701 Phase 1/2 ORR 47.6% HNSCC, 55.6% mUC at ESMO25","bullets":["3.6 mg/kg dose: ORR 47.6% in HNSCC (n=21), 37.5% in cervical cancer (n=16), 55.6% in mUC (n=9).","No grade 4/5 treatment-related AEs; low discontinuation rate (6.0%) and peripheral neuropathy (8.4% Grade 1/2).","Responses seen regardless of Nectin-4, HPV, or PD-L1 status; median prior therapies = 3.","Company plans FDA meeting in 2025 and registrational studies by mid-2026.","Data presented at ESMO25 from 167 patients; 122 evaluable for efficacy."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-243046","json":"https://secwatch.observer/filing/0001193125-25-243046.json","markdown":"https://secwatch.observer/filing/0001193125-25-243046.md","text":"https://secwatch.observer/filing/0001193125-25-243046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000119312525243046/0001193125-25-243046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000119312525243046/crbp-20251018.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:13:37.300837+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}